HFZS
839725
Hangzhou SDIC Microelectronics Inc.
688130
Henan Liliang Diamond
301071
Sf Diamond Co., Ltd.
300179
Jiangsu Zhengdan Chemical Industry
300641
CN Stock MarketDetailed Quotes
301060 Shanghai Labway Clinical Laboratory
- 9.74
- -0.63-6.08%
Market Closed Dec 23 15:00 CST
3.90BMarket Cap-21.50P/E (TTM)
10.34High9.70Low94.66KlotVolume10.34Open10.37Pre Close93.88MTurnover2.66%Turnover RatioLossP/E (Static)400.52MShares14.7752wk High2.25P/B3.47BFloat Cap7.3452wk Low12.44Limit Up356.58MShs Float60.60Historical High8.30Limit Down6.17%Amplitude7.34Historical Low--Dividend TTM9.92Avg Price56.70KlotAsk--Div YieldTTM100Lot Size36.36KlotBid
Shanghai Labway Clinical Laboratory Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 3.95%1.32B | 6.00%888.22M | 5.78%436.44M | -60.13%1.67B | -59.15%1.27B | -59.34%837.91M | -50.15%412.59M | 136.14%4.2B | 143.91%3.11B | 167.17%2.06B |
| Operating revenue | 3.95%1.32B | 6.00%888.22M | 5.78%436.44M | -60.13%1.67B | -59.15%1.27B | -59.34%837.91M | -50.15%412.59M | 136.14%4.2B | 143.91%3.11B | 167.17%2.06B |
| Other operating revenue | ---- | -96.05%157.57K | ---- | -61.58%6.72M | ---- | -13.28%3.99M | ---- | 46.94%17.5M | ---- | 168.90%4.6M |
| Total operating cost | 7.99%1.3B | 9.51%855.56M | 11.25%410.5M | -45.13%1.69B | -45.04%1.2B | -44.73%781.25M | -32.76%368.99M | 109.92%3.07B | 117.79%2.19B | 126.06%1.41B |
| Operating cost | 8.76%1.04B | 10.22%686.09M | 16.48%340.84M | -44.95%1.33B | -45.16%958.85M | -43.25%622.49M | -32.07%292.61M | 119.30%2.41B | 126.05%1.75B | 129.76%1.1B |
| Operating tax surcharges | 49.61%5.12M | 31.60%2.53M | 20.88%1.16M | -12.88%4.76M | 1.10%3.43M | -13.89%1.92M | -16.69%961.53K | 10.84%5.47M | -11.87%3.39M | -3.90%2.23M |
| Operating expense | -17.24%57.78M | -18.52%37.8M | -19.34%17.25M | -46.40%98.69M | -48.87%69.82M | -51.93%46.39M | -48.55%21.39M | 46.73%184.12M | 76.81%136.54M | 81.09%96.49M |
| Administration expense | 5.38%142.64M | 7.89%96.26M | -1.52%41.86M | -42.80%203.37M | -44.91%135.35M | -51.66%89.22M | -32.00%42.5M | 83.62%355.54M | 94.79%245.71M | 140.86%184.59M |
| Financial expense | 140.88%4.95M | 115.39%3.42M | -176.34%-592.43K | -54.89%3.45M | -60.68%2.06M | 3.67%1.59M | 180.31%776.06K | 625.94%7.64M | 564.05%5.23M | 377.71%1.53M |
| -Interest expense (Financial expense) | 29.05%8.05M | 50.83%5.89M | 30.77%2.85M | -3.41%8.17M | 12.18%6.24M | 68.39%3.91M | 188.46%2.18M | 158.98%8.46M | 134.66%5.56M | 44.46%2.32M |
| -Interest Income (Financial expense) | 16.45%-3.99M | -23.04%-3.27M | -30.28%-1.82M | -100.72%-5.58M | -152.15%-4.77M | -101.94%-2.66M | -104.55%-1.4M | -3.35%-2.78M | 1.42%-1.89M | 10.40%-1.32M |
| Research and development | 37.36%44.92M | 50.09%29.47M | -7.14%9.99M | -55.34%48.86M | -32.33%32.7M | -38.08%19.63M | -13.92%10.75M | 177.38%109.4M | 110.16%48.32M | 107.76%31.71M |
| Credit Impairment Loss | 58.96%-30.77M | 69.21%-24.13M | 34.77%-23.17M | -136.56%-129.13M | -137.64%-74.98M | -346.98%-78.35M | -741.55%-35.52M | -270.01%-54.59M | -176.42%-31.55M | -88.33%-17.53M |
| Asset Impairment Loss | -725.06%-68.18M | -74.57%-4.71M | -133.37%-1.64M | 78.78%-28.94M | -32.48%-8.26M | 34.53%-2.7M | 65.58%-700.77K | -1,849.87%-136.37M | -95.22%-6.24M | -48.38%-4.12M |
| Other net revenue | -33.25%-82.62M | 68.08%-20.05M | -10.26%-23.22M | 30.17%-124.98M | -116.76%-62M | -376.27%-62.79M | -2,863.09%-21.06M | -5,082.27%-178.97M | -4,589.90%-28.6M | -619.03%-13.18M |
| Fair value change income | ---- | ---- | ---- | ---- | ---- | ---- | --0 | -57.66%1.66M | 330.88%1.66M | -21.72%1.66M |
| Invest income | 296.84%4.52M | 368.67%4.47M | 74.43%-221.69K | -383.29%-2.12M | -209.13%-2.3M | -163.01%-1.67M | -147.24%-867.04K | -88.01%748.08K | -59.86%2.11M | -19.58%2.64M |
| -Including: Investment income associates | 48.01%-1.14M | 38.73%-879.1K | 49.21%-389.36K | -44.79%-2.33M | -335.47%-2.19M | ---1.43M | ---766.56K | ---1.61M | ---503.51K | ---- |
| Asset deal income | -112.56%-188.51K | 106.69%45.66K | 56.30%-131.5K | 631.38%1.93M | 513.54%1.5M | -612.09%-682.49K | -494.41%-300.95K | -135.03%-363.15K | -71.44%244.58K | -72.03%133.28K |
| Other revenue | -45.56%12M | -79.26%4.27M | -88.14%1.94M | 234.92%33.29M | 326.28%22.03M | 411.61%20.6M | 374.26%16.33M | -29.67%9.94M | -40.97%5.17M | -53.91%4.03M |
| Operating profit | -1,173.14%-60.87M | 305.82%12.62M | -87.93%2.72M | -114.31%-135.82M | -99.36%5.67M | -100.97%-6.13M | -91.94%22.54M | 197.63%949.28M | 229.64%892.73M | 326.66%634.09M |
| Add:Non operating Income | 485.79%1.18M | 491.34%925.27K | 269.40%249.52K | -62.87%589.88K | 60.04%200.78K | 109.73%156.47K | -14.70%67.55K | -18.73%1.59M | -93.35%125.45K | -59.11%74.61K |
| Less:Non operating expense | -7.06%4.98M | -54.40%2.35M | -78.15%651.77K | -61.20%18.01M | -58.05%5.36M | -11.47%5.16M | -5.33%2.98M | 1,516.95%46.42M | 689.92%12.77M | 696.79%5.82M |
| Total profit | -12,685.95%-64.67M | 200.55%11.19M | -88.19%2.32M | -116.94%-153.24M | -99.94%513.85K | -101.77%-11.13M | -92.91%19.63M | 184.39%904.44M | 224.65%880.08M | 324.35%628.34M |
| Less:Income tax cost | -216.32%-11.49M | -83.44%1.1M | -36.00%2.58M | -94.88%8.47M | -93.29%9.88M | -93.44%6.67M | -91.13%4.04M | 193.17%165.39M | 219.97%147.16M | 285.29%101.63M |
| Net profit | -467.72%-53.18M | 156.68%10.09M | -101.70%-264.83K | -121.88%-161.71M | -101.28%-9.37M | -103.38%-17.8M | -93.26%15.59M | 182.50%739.06M | 225.61%732.92M | 332.82%526.71M |
| Net profit from continuing operation | -467.72%-53.18M | 156.68%10.09M | -101.70%-264.83K | -121.88%-161.71M | -101.28%-9.37M | -103.38%-17.8M | -93.26%15.59M | 182.50%739.06M | 225.61%732.92M | 332.82%526.71M |
| Less:Minority Profit | -48.41%-12.6M | 65.50%-5.51M | 77.04%-1.34M | -116.53%-20.12M | -106.60%-8.49M | -116.61%-15.97M | -110.80%-5.82M | 110.70%121.73M | 169.42%128.6M | 309.00%96.16M |
| Net profit of parent company owners | -4,511.40%-40.58M | 955.77%15.6M | -95.00%1.07M | -122.94%-141.59M | -100.15%-880.08K | -100.42%-1.82M | -87.92%21.41M | 202.85%617.32M | 240.73%604.32M | 338.53%430.55M |
| Earning per share | ||||||||||
| Basic earning per share | -4,563.64%-0.1026 | 945.65%0.0389 | -94.95%0.0027 | -122.94%-0.3535 | -100.15%-0.0022 | -100.43%-0.0046 | -87.91%0.0535 | 166.52%1.5413 | 199.84%1.5088 | 285.86%1.075 |
| Diluted earning per share | -4,563.64%-0.1026 | 945.65%0.0389 | -94.95%0.0027 | -122.94%-0.3535 | -100.15%-0.0022 | -100.43%-0.0046 | -87.91%0.0535 | 166.52%1.5413 | 199.84%1.5088 | 285.86%1.075 |
| Other composite income | -653.31K | |||||||||
| Other composite income of parent company owners | ---- | ---- | ---- | ---653.31K | ---- | ---- | ---- | ---- | ---- | ---- |
| Total composite income | -467.72%-53.18M | 156.68%10.09M | -101.70%-264.83K | -121.97%-162.36M | -101.28%-9.37M | -103.38%-17.8M | -93.26%15.59M | 182.50%739.06M | 225.61%732.92M | 332.82%526.71M |
| Total composite income of parent company owners | -4,511.40%-40.58M | 955.77%15.6M | -95.00%1.07M | -123.04%-142.24M | -100.15%-880.08K | -100.42%-1.82M | -87.92%21.41M | 202.85%617.32M | 240.73%604.32M | 338.53%430.55M |
| Total composite income of minority owners | -48.41%-12.6M | 65.50%-5.51M | 77.04%-1.34M | -116.53%-20.12M | -106.60%-8.49M | -116.61%-15.97M | -110.80%-5.82M | 110.70%121.73M | 169.42%128.6M | 309.00%96.16M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
